arrow
M

María Dolores Martin-Arranz

Hospital Universitario La Paz
H指数:30
被引数:3,390

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics, management, and long-term outcomes of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease: Data from the ENEIDA registry

炎症性肠病中坏疽性脓皮病和结节性红斑的特征、管理及长期结局:ENEIDA登记研究数据

2026-11-030
PRE
Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease

新诊断炎症性肠病患者生物制剂治疗、住院及手术的临床过程与预测因素:一项为期五年的前瞻性研究

2026-10-110
OAAI
Self-expandable metal stents versus endoscopic balloon dilatation for the treatment of strictures in Crohn’s disease: a retrospective long-term follow-up of the ProtDilat study, an open label, multicenter, randomized trial

克罗恩病狭窄治疗中自膨胀金属支架与内镜球囊扩张的比较:ProtDilat研究(一项开放标签、多中心、随机试验)的长期随访回顾研究

2026-09-180
OAAI
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry

瑞莎珠单抗在难治性克罗恩病中的真实世界有效性:来自ENEIDA登记研究的RISANCROHN研究

2026-06-100
PRE
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

真实世界中乌帕替尼治疗克罗恩病的有效性与安全性:来自Eneida注册研究的启示

2026-04-300
OAAI
Factors Influencing Clinical and Radiological Response in Perianal Disease: Results from a Real-World Cohort Treated with Anti-TNF Therapy

影响肛周疾病临床和放射学反应的因素:接受抗TNF治疗的真实世界队列研究结果

2026-03-050
OAAI
Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study)

vedolizumab在难治性直肠炎中的真实世界有效性:重点关注从静脉给药转换为皮下给药期间生物标志物的变化(POUCHIVED研究)

2025-12-170
OAAI
Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study

英夫利昔单抗与阿达木单抗在克罗恩病中的比较疗效和免疫原性:一项前瞻性队列研究

2025-12-040
OAAI
Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry

老年患者术后克罗恩病的治疗管理及预后比较研究:ENEIDA登记研究数据

2025-12-010
OAAI
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicity

硫嘌呤毒性的新见解:稀有XDH变异体对骨髓毒性的贡献

2025-08-130
PREAI
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Effectiveness of Upadacitinib in Patients with Baseline Active Extraintestinal Manifestations and Inflammatory Bowel Disease. A multicenter retrospective study
2025-01-220
PRE
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
2025-01-220
PRE
Time-trends in the management of postoperative Crohn's Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry
2025-01-220
PRE
Real-World Outcomes of Upadacitinib in Crohn's Disease: Insights from ENEIDA database
2025-01-220
PRE
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
2025-01-220
PRE